Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5795569

Title:Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
Inventors:Bartley, Timothy D.; Thousand Oaks, CA, USA
Bogenberger, Jakob M.; Camarillo, CA, USA
Bosselman, Robert A.; Thousand Oaks, CA, USA
Hunt, Pamela; Thousand Oaks, CA, USA
Kinstler, Olaf B.; Oxnard, CA, USA
Samal, Babru B.; Moorpark, CA, USA
Summary:This invention discloses the properties of novel proteins, referred to as megakaryocyte growth and development factors. Such MGDFs are also generally known as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately resulting in the production of platelets. Also described are MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, along with methods for their preparation. Further descriptions include processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.
Abstract:Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5795569
Application Number:US1994000321488
Date Filed:12/10/1994
Date Published:18/08/1998
Assignee:Amgen Inc., Thousand Oaks, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021